Trailing-twelve-month (TTM) revenue is $57.57 Million with a year-over-year growth of (13.27%). Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q1 FY2026Period ended 2025-09-30 | $13,888,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-13 |
| Q2 FY2026Period ended 2025-12-31 | $15,165,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-03 |
| Q3 FY2026Period ended 2026-03-31 | $12,411,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-13 |
| Q4 FY2026Period ended 2026-06-30 | $16,106,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-09-22 |
| TTM revenue | $57,570,000 |
Current P/S: $22,432,388 market capitalization ÷ $57,570,000 TTM revenue = 0.39x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T14:44:52.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q4 FY2026 (2026-06-30): $16.11M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T15:05:46.877Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2024-06-30 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2024-06-30 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20172017-06-30 · USD | FY20202020-06-30 · USD | FY20212021-06-30 · USD | FY20222022-06-30 · USD | FY20232023-06-30 · USD | FY20242024-06-30 · USD |
|---|---|---|---|---|---|---|
| Aytu Bio Pharma | N/A | N/A | $33M | N/A | N/A | N/A |
| AYTU Bioscience, Inc. | $3M | N/A |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20152015-06-30 · USD | FY20212021-06-30 · USD | FY20222022-06-30 · USD | FY20232023-06-30 · USD | FY20242024-06-30 · USD |
|---|---|---|---|---|---|
| KOREA, REPUBLIC OF | $500,000 | N/A | N/A | N/A | N/A |
| Non Us | N/A | $5M | N/A | N/A | N/A |
$57.57M
$57.57 Million
(13.27%)
vs. $66.38M a year ago (TTM)
(2.59%)
5 Year compound annual growth rate
1 Year
(13.27%)
3 Year
(18.76%)
5 Year
(2.59%)
10 Year
+36.51%
15 Year
N/A
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2026 | $57.57M | ($8.81M) | (13.27%) |
| 2025 | $66.38M | +$1.20M | +1.84% |
| 2024 | $65.18M | ($42.22M) | (39.31%) |
| 2023 | $107.40M | +$10.73M | +11.10% |
| 2022 | $96.67M | +$31.04M | +47.29% |
| 2021 |
TTM Growth
(13.27%)
3-Year CAGR
(18.76%)
5-Year CAGR
(2.59%)
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T15:05:46.877Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
| N/A |
| N/A |
| N/A |
| N/A |
| Aytu Consumer Health | N/A | N/A | $33M | N/A | N/A | N/A |
|---|
| Aytu Women's Health | $47,000 | N/A | N/A | N/A | N/A | N/A |
|---|
| Consumer Health | N/A | N/A | N/A | N/A | $34M | $16M |
|---|
| Consumer Health Portfolio | N/A | N/A | N/A | $36M | N/A | N/A |
|---|
| License Revenue | N/A | $0 | N/A | N/A | N/A | N/A |
|---|
| Pediatric Portfolio | N/A | N/A | N/A | $16M | N/A | N/A |
|---|
| Product Revenue | N/A | $28M | N/A | N/A | N/A | N/A |
|---|
| Non-US | N/A | N/A | $2M | $481,000 | $91,000 |
|---|
| UNITED STATES | N/A | N/A | $95M | $107M | $81M |
|---|
| $65.63M |
| +$38.00M |
| +137.52% |
| 2020 | $27.63M | +$20.31M | +277.47% |
| 2019 | $7.32M | +$3.66M | +100.01% |
| 2018 | $3.66M | +$438,410 | +13.61% |
| 2017 | $3.22M | +$659,145 | +25.72% |
